Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome

Evaluation of the Gastrinoma in Patients With Zollinger-Ellison Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00001254

Enrollment

273

Registered

1999-11-04

Start date

1991-10-29

Completion date

Unknown

Last updated

2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zollinger Ellison Syndrome

Keywords

Zollinger-Ellison Syndrome, Natural History

Brief summary

This protocol concerns the approach to the localization, diagnosis of MEN1 and management of the tumor and the tissue samples in patients with Zollinger-Ellison syndrome. It details the diagnostic imaging tests to be used to localize the tumor, investigations for MEN1 the subsequent management of the tumor and tissue samples for research.

Detailed description

This protocol concerns the approach to the localization and management of the tumor in patients with Zollinger-Ellison syndrome. It details the diagnostic imaging tests to be used to localize the tumor and the subsequent management of the tumor.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: New patients will be evaluated initially as described in the protocol entitled, "Diagnostic evaluation of patients with suspected abnormalities of gastric secretion" (89-DK-0005). Only those patients that are being treated under the protocol entitled, "Medical Therapy of Zollinger-Ellison Syndrome" (protocol # 89-DK-0015) will be entered into this tumor localization and management protocol.

Design outcomes

Primary

Measure	Time frame	Description
To determine an approach to the localization and management of tumor in patients with ZES.	Yearly	localization of tumor

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRobert T Jensen, M.D.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Outcome results